Prostatype Genomics AB (publ) (PROGEN.ST)
SEK 10.3
(-8.04%)
SEK 10.3
(-8.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 67 Thousand SEK | -92.27% |
| 2022 | 866.66 Thousand SEK | -31.58% |
| 2021 | 1.26 Million SEK | -13.64% |
| 2020 | 1.46 Million SEK | 0.0% |
| 2018 | 6.85 Million SEK | -28.44% |
| 2017 | 9.57 Million SEK | 358.5% |
| 2016 | 2.08 Million SEK | -46.79% |
| 2015 | 3.92 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q4 | 11.66 Million SEK | 0.0% |
| 2023 FY | 67 Thousand SEK | -92.27% |
| 2023 Q3 | 11.66 Million SEK | 1650.71% |
| 2023 Q2 | 666.41 Thousand SEK | -13.05% |
| 2023 Q1 | 766.41 Thousand SEK | -11.57% |
| 2022 Q4 | 866.66 Thousand SEK | -10.34% |
| 2022 Q3 | 966.66 Thousand SEK | -9.37% |
| 2022 FY | 866.66 Thousand SEK | -31.58% |
| 2022 Q2 | 1.06 Million SEK | -8.57% |
| 2022 Q1 | 1.16 Million SEK | -7.89% |
| 2021 FY | 1.26 Million SEK | -13.64% |
| 2021 Q2 | 1.46 Million SEK | 2.33% |
| 2021 Q1 | 1.43 Million SEK | -2.27% |
| 2021 Q4 | 1.26 Million SEK | -7.32% |
| 2021 Q3 | 1.36 Million SEK | -6.82% |
| 2020 Q3 | 5.65 Million SEK | -67.11% |
| 2020 Q2 | 17.18 Million SEK | 0.0% |
| 2020 FY | 1.46 Million SEK | 0.0% |
| 2020 Q4 | 1.46 Million SEK | -74.05% |
| 2019 Q3 | 1.76 Million SEK | 0.0% |
| 2018 FY | 6.85 Million SEK | -28.44% |
| 2017 FY | 9.57 Million SEK | 358.5% |
| 2016 FY | 2.08 Million SEK | -46.79% |
| 2015 FY | 3.92 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AroCell AB (publ) | - SEK | -Infinity% |
| Devyser Diagnostics AB (publ) | 74.8 Million SEK | 99.91% |
| Immunovia AB (publ) | 4.28 Million SEK | 98.437% |
| SenzaGen AB | 1.67 Million SEK | 95.995% |
| Spermosens AB | 9.51 Million SEK | 99.296% |